Abbott Laboratories 2014 Annual Report Download - page 40

Download and view the complete annual report

Please find page 40 of the 2014 Abbott Laboratories annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 80

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80

ABBOTT 2014 ANNUAL REPORT
38
Year Ended December 31 2014 2013 2012
Common Shares:
Beginning of Year
Shares: 2014: 1,685,827,096; 2013: 1,675,930,484; 2012: 1,638,870,201 $12,048 $11,755 $÷9,817
Issued under incentive stock programs
Shares: 2014: 9,102,853; 2013: 9,896,612; 2012: 37,060,283 404 393 1,854
Share-based compensation 245 261 435
Issuance of restricted stock awards (314) (361) (351)
End of Year
Shares: 2014: 1,694,929,949; 2013: 1,685,827,096; 2012: 1,675,930,484 $12,383 $12,048 $11,755
Common Shares Held in Treasury:
Beginning of Year
Shares: 2014: 137,728,810; 2013: 99,262,992; 2012: 68,491,382 $«(6,844) $«(5,591) $«(3,688)
Issued under incentive stock programs
Shares: 2014: 5,818,599; 2013: 5,718,575; 2012: 6,691,748 283 310 363
Purchased
Shares: 2014: 54,984,304; 2013: 44,184,393; 2012: 37,463,358 (2,117) (1,563) (2,266)
End of Year
Shares: 2014: 186,894,515; 2013: 137,728,810; 2012: 99,262,992 $«(8,678) $«(6,844) $«(5,591)
Earnings Employed in the Business:
Beginning of Year $21,979 $24,151 $20,907
Net earnings 2,284 2,576 5,963
Separation of AbbVie Inc. — (3,735) —
Cash dividends declared on common shares
(per share—2014: $0.90; 2013: $0.64; 2012: $1.67) (1,363) (1,002) (2,650)
Eect of common and treasury share transactions (26) (11) (69)
End of Year $22,874 $21,979 $24,151
Accumulated Other Comprehensive Income (Loss):
Beginning of Year $«(2,012) $«(3,594) $«(2,597)
Separation of AbbVie Inc. — 1,010 —
Other comprehensive income (loss) (3,041) 572 (997)
End of Year $«(5,053) $«(2,012) $«(3,594)
Noncontrolling Interests in Subsidiaries:
Beginning of Year $÷÷÷«96 $÷÷÷«92 $÷÷÷«86
Noncontrolling Interests’ share of income, business combinations,
net of distributions and share repurchases 17 4 6
End of Year $÷÷«113 $÷÷÷«96 $÷÷÷«92
The accompanying notes to consolidated financial statements are an integral part of this statement.
CONSOLIDATED STATEMENT OF SHAREHOLDERS’ INVESTMENT
(inmillions except shares and per share data)